Touring @SAiGENCI Level 9 facilities at AHMS Building with Director Designate, @ChrisSweens1

"Very favorable" risk group of mRCC was presented @ASCOGU21 by @dr_aschmidt We externally validated the novel IMDC risk model in "Turkish Oncology Group Kidney Cancer Consortium" database @DrYukselUrun @DrChoueiri @DrDanielHeng @OncoAlert 👇 https://t.co/hYTAdDJARE

Great summary of TKI adjuvant trials in RCC by @apolo_andrea Only STRAC showed a significant DFS benefit. Despite FDA approval not used widely, with toxicity issues and lack of OS

1/ Excited to share our work @COVID19nCCC on Breakthrough COVID-19 in Patients with Cancer @Annals_Oncology Team effort with @Chrislabaki1 @ZiadBakouny @DFarmakiotis @hemoncwarner @DrChoueiri

1/ Thrilled to see our work on #COVID19 vaccination in pts with cancer from #CCC19 published. W/ co-1st authors @dr_aschmidt @Chrislabaki1 C-Y Hsu! @Annals_Oncology @COVID19nCCC The crux of it is that even w/ vaccination, some pts w/ cancer (heme ++) remain at high risk

Congratulations @dr_aschmidt et al for this important work! 👍 💉 😷 🦠

1/Excited to share our work on COVID-19 breakthrough infections in patients w/cancer in @Annals_Oncology. Efforts led by co-1st authors @dr_aschmidt, @Chrislabaki1, C-Y. Hsu, @ZiadBakouny and co-seniors: @jeremywarner #YuShyr & @farmakiotis @COVID19nCCC https://t.co/OOCwnZHR7P

HIF-2α inhibition shows ‘encouraging results’ in kidney cancer trial. Study led by Dana-Farber’s Toni Choueiri, MD (@DrChoueiri), and published in @NatureMedicine looks at belzutifan in patients with metastatic renal cell carcinoma: https://t.co/2qRZw31Pir cc @DanaFarber_GU

Recent IO trials have not progressed the field much in prostate cancer outside of MSI. Thank you @xiaoweimd @DanaFarber_GU summarising upcoming IO trials - https://t.co/KvfAltd3fN

Fantastic summary from @ChrisSweens1 summarising mHSPC data for Docetaxel at the 20th Biennial Course in Urologic Oncology. Volume and time to mets refine benefit @Chrislabaki1 @ZiadBakouny

Latest PCOR-Vic🇦🇺registry data on docetaxel use in mHS #ProstateCancer. From 2014-18, 25% received docetaxel with age + Rx in private hosp. A/W sig.⬆︎chemo use. In 2018, 70% of <70yo Rx with docetaxel. RW impact of CHAARTED & STAMPEDE! https://t.co/fn2UzHH4tU

#COVID19 #vaccines immune effect on cancer patients. @DanaFarber is looking for patients with GU/Breast cancer who plan to get the vaccine to participate in our new study: VERIFY-C, to determine immune responses. Please reach out to VerifyC@DFCI.harvard.edu @stolaney1 @nlinmd

Thank you to the team at @DanaFarber_GU, our co-authors and our mentors @DrChoueiri @qdtrinh for making this work possible.

7/ From ASCO GU 21 - look at field expert @_ShankarSiva report on SBRT + IO in oligometastatic disease https://t.co/fexOesITsq @DrBenTran @AzadOncology @declangmurphy

6/ Effective front line therapies provide increased opportunity for integration of SBRT, either to mets or to the primary. Watch out for CYTOSHRINK in Canada/AUS: Nivo-Ipi +/-SBRT to the primary NRG SAMURAI in USA; Nivo-Ipi or VEGF-IO +/-SBRT to the primary @DrRanaMcKay

5/ Overall SBRT use for mRCC is increasing but is still utilised for only a minority of patients. Key sociodemographic differences in the receipt of SBRT are evident.

4/ Factors associated with a higher odds of receiving SBRT included - later year of diagnosis and - higher educational status. Independent predictors of lower likelihood of receipt of SBRT were - female - Black race - Insurance status (Medicaid insurance or no insurance)

3/ More patients are receiving SBRT: 1.4% in 2004 to 3.7% in 2016. Conventional RT use is decreasing: 26.6% in 2004 to 24.1% in 2016. The most common sites for SBRT CNS disease (75.1%) and spine (14.5%) Compared to conventional RT spine (35.6%) and other bony sites (24.5%)

2/ Using the NCDB, we looked at temporal trends and clinical predictors of utilisation in the US between 2004-2016 Of 65,345 patients diagnosed with mRCC 1,919 (2.9%) underwent SBRT 15,871 (24.3%) received conventional RT 47,555 (72.8%) did not receive RT for mRCC

1/ SBRT is useful to treat symptomatic sites or where oligomets/progression is present. Once considered resistant to RT, modern techniques like SBRT demonstrate excellent locoregional control rates for mRCC. Little is known about community utilization in the US